Business Context and Reporting Period
This Form 8-K Current Report was filed by Aardvark Therapeutics, Inc. on December 10, 2025. The filing addresses Item 8.01 Other Events, specifically announcing a significant milestone in the Company's Phase 3 HERO pivotal clinical trial for ARD-101, a treatment for hyperphagia in individuals with Prader-Willi syndrome.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or quantitative financial data.
Material Changes and Clinical Progress
- First Patient Dosed: The first patient was dosed in Australia for the Phase 3 HERO trial.
- Regulatory Clearances: Enrollment clearance has been received for clinical trial sites in Canada and the United Kingdom.
- Site Activation Strategy: The Company anticipates it will not need to activate previously planned sites in the European Union to fully enroll the trial.
Guidance, Outlook, and Management Commentary
Management expects to meet the anticipated timeline for the topline data readout in the third quarter of 2026. The decision to forego activating EU sites suggests the current enrollment rate in Australia, Canada, and the UK is sufficient to meet the trial's timeline objectives.
Investor Verification Checklist
- Verify the full text of the press release filed as Exhibit 99.1 for detailed enrollment numbers.
- Confirm the specific timeline for the third-quarter 2026 topline data readout in subsequent filings.
- Monitor future 8-K filings for any updates regarding the activation status of EU sites or changes to the enrollment strategy.
- Review the Company's most recent 10-K or 10-Q for current cash runway and liquidity status, as this 8-K does not contain financial data.